Alternation in glucagon secretion by dietary intake after administration of sodium glucose transporter-2 inhibitor.

Not Applicable

Completed

• Conditions: Type 2(non-insulin dependent) diabetes mellitus

• Registration Number: JPRN-UMIN000021977
• Lead Sponsor: Kitasato University, School of Medicine

Brief Summary

Primary endpoint There was no significant change in glucagon fluctuation before and after Luseogliflozin administration. Secondary endpoint 1. GLP-1 secretion during meal tolerance test increased after Luseogliflozin administration but GIP secretion did not change. 2. The secretion ratio of glucagon to insulin, GLP-1, and GIP during meal tolerance test were not changed. 3. HOMA-R and Matsuda index were both improved, as were HOMA-beta and Disposition index.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-05-01
• Study Completion: 2020-07-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

Not provided

Exclusion Criteria

1. A patient suffering from acute disease 2. In case of malignacy 3. Renal dysfunction (estimeted GFR <60ml/min) 4. Liver dysfunction (AST >100U/l, ALT >100U/l) 5. Pregnant or possibility of pregnant 6. Lactating mothers 7. A patient suffering from endocrine disorders 8. A patient administrated any drugs affect glucose metabolism 9. Diabetic patients who have taken any hypoglycemic agents include SGLT-2 inhibitor in proximate 6 months 10.A patient undergoing or having history of treatment for ischemic heart disease 11.Chronic heart failure (NYHA class 2 or worse) 12.A patient undergoing or having history of treatment for cerebro-vascular disease 13.A patient undergoing or multiple (3 times or more) history of urinary or genital tract infection 14.A patient accompanied with severe diabetic retinopathy, nephropathy, neuropathy 15.A patient in hyperglycemic crisis or accompanied with marked symptom of hyperglycemia 16.Taking diuretics 17.Correspond to contraindication of Luseogliflozin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The alternation in glucagon secretion pattern by dietary intake before and after 12 weeks administration of sodium glucose transporter-2(SGLT-2) inhibitor.